May 4, 2021 | Letters Supported
The undersigned organizations are writing, in anticipation of the reintroduction of the Elijah E. Cummings Lower Drug Costs Now Act (i.e., H.R. 3), to urge Congress to keep any international reference pricing proposals (including “International Pricing...
Read more
May 4, 2021 | Letters Supported
Patient groups, advocates, and providers have seen disturbing media reports about Cigna’s recent letter to patients and providers regarding the use of Cosentyx. In the letter, patients are encouraged to switch to a Cigna-preferred drug, as Cosentyx was removed from...
Read more
Mar 29, 2021 | Access, Federal Issues, Letters Supported
On behalf of the undersigned organizations representing diverse patient and provider stakeholders who are concerned with the effects of rebate walls on patient treatment access, we greatly appreciate your leadership on critical efforts to protect patient well-being....
Read more
Mar 18, 2021 | Copay Accumulators, Letters Supported
New York has a strong record in leading the nation in providing access to affordable health coverage. Despite the strides the state has made in expanding coverage, many New Yorkers still face hardship when faced with prescription drug costs. New Yorkers and others...
Read more
Jan 25, 2021 | Letters Supported, Step Therapy
The American Autoimmune Related Diseases Association (AARDA), other patient advocates and providers understand that UnitedHealthcare intends to move Remicade from preferred to non-preferred coverage in February 2021. This abrupt change by the plan could be disruptive...
Read more
Aug 25, 2020 | Copay Assistance, COVID-19, Letters Supported
On behalf of the undersigned organizations and over 45 million persons covered by Medicare Part D and their family caregivers, we urge you to rescind the current ban on the use of copay cards in the Medicare Part D program at least through the current Novel...
Read more
